[{"orgOrder":0,"company":"Fulgent Pharma","sponsor":"Fulgent Genetics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2022","type":"Acquisition","leadProduct":"Paclitaxel","moa":"Microtubules","graph1":"Oncology","graph2":"Phase I","graph3":"Fulgent Pharma","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injectable\/Injection","sponsorNew":"Fulgent Pharma \/ Fulgent Genetics","highestDevelopmentStatusID":"6","companyTruncated":"Fulgent Pharma \/ Fulgent Genetics"}]

Find Clinical Drug Pipeline Developments & Deals by Fulgent Pharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmtech & Ingredients
                          Not Confirmed
                          Pharmtech & Ingredients
                          Not Confirmed

                          Details : FID-007 consists of paclitaxel encapsulated in a polyethyloxazoline polymer excipient designed to enhance PK, biodistribution, and tolerability. The PEOX nanoparticle is designed to preferentially deliver paclitaxel to the tumor through the leaky hyperpe...

                          Brand Name : FID-007

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          November 07, 2022

                          Lead Product(s) : Paclitaxel

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase I

                          Sponsor : Fulgent Genetics

                          Deal Size : $100.0 million

                          Deal Type : Acquisition

                          blank